References
- Terrando N, Brzezinski M, Degos V, et al. Perioperative cognitive decline in the aging population. Mayo Clin Proc 2011;86:885–93.
- Monk TG, Weldon BC, Garvan CW, et al. Predictors of cognitive dysfunction after major noncardiac surgery. Anesthesiology 2008;108:18–30.
- Rosczyk HA, Sparkman NL, Johnson RW. Neuroinflammation and cognitive function in aged mice following minor surgery. Exp Gerontol 2008;43:840–6.
- He HJ, Wang Y, Le Y, et al. Surgery upregulates high mobility group box-1 and disrupts the blood–brain barrier causing cognitive dysfunction in aged rats. CNS Neurosci Ther 2012;18:994–1002.
- Li M, Yong-Zhe L, Ya-Qun M, et al. Ulinastatin alleviates neuroinflammation but fails to improve cognitive function in aged rats following partial hepatectomy. Neurochem Res 2013;38:1070–7.
- Gveric D, Herrera B, Petzold A, et al. Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 2003;126:1590–8.
- Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood–brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010;38:376–85.
- Shigemori Y, Katayama Y, Mori T, et al. Matrix metalloproteinase-9 is associated with blood–brain barrier opening and brain edema formation after cortical contusion in rats. Acta Neurochir Suppl 2006;96:130–3.
- Barichello T, Generoso JS, Michelon CM, et al. Inhibition of matrix metalloproteinases-2 and -9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats. Exp Biol Med (Maywood) 2014;239:225–31.
- Scaini G, Morais MO, Galant LS, et al. Coadministration of branched-chain amino acids and lipopolysaccharide causes matrix metalloproteinase activation and blood–brain barrier breakdown. Mol Neurobiol 2014;50:358–67.
- Ludewig P, Sedlacik J, Gelderblom M, et al. Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits MMP-9-mediated blood–brain-barrier breakdown in a mouse model for ischemic stroke. Circ Res 2013;113:1013–22.
- Wang Z, Meng CJ, Shen XM, et al. Potential contribution of hypoxia-inducible factor-1α, aquaporin-4, and matrix metalloproteinase-9 to blood–brain barrier disruption and brain edema after experimental subarachnoid hemorrhage. J Mol Neurosci 2012;48:273–80.
- Shen F, Cai WS, Li JL, et al. Synergism from the combination of ulinastatin and curcumin offers greater inhibition against colorectal cancer liver metastases via modulating matrix metalloproteinase-9 and E-cadherin expression. Onco Targets Ther 2014;7:305–14.
- Huang WB, Shen J, Zhang L, et al. Protective effects of ulinastatin on phosgene-induced acute lung injury and relation to matrix metalloproteinase-9. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2010;28:498–504.
- Xu B, Li KP, Shen F, et al. Ulinastatin reduces cancer recurrence after resection of hepatic metastases cells. Anticancer Res 2005;25:815–20.
- Kobayashi H, Suzuki M, Tanaka Y, et al. Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways. J Biol Chem 2001;276(3):2015–22.
- Kobayashi H, Suzuki M, Sun GW, et al. Suppression of urokinase-type plasminogen activator expression from human ovarian cancer cells by urinary trypsin inhibitor. Biochim Biophys Acta 2000;1481:310–6.
- Luo J, Sun X, Gao F, et al. Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERK. J Exp Clin Cancer Res 2011;30:71.
- Yepes M, Sandkvist M, Moore EG, et al. Tissue-type plasminogen activator induces opening of the blood–brain barrier via the LDL receptor-related protein. J Clin Invest 2003;112:1533–40.
- Northrop NA, Yamamoto BK. Persistent neuroinflammatory effects of serial exposure to stress and methamphetamine on the blood–brain barrier. J Neuroimmune Pharmacol 2012;7:951–68.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402–8.
- Tao F, Johns RA. Effect of disrupting N-methyl-D-aspartate receptor-postsynaptic density protein-95 interactions on the threshold for halothane anesthesia in mice. Anesthesiology 2008;108:882–7.
- Hovens IB, Schoemaker RG, van der Zee EA, et al. Postoperative cognitive dysfunction: involvement of neuroinflammation and neuronal functioning. Brain Behav Immun 2014;38:202–10.
- Vacas S, Degos V, Feng X, Maze M. The neuroinflammatory response of postoperative cognitive decline. Br Med Bull 2013;106:161–78.
- Le Y, Liu S, Peng M, et al. Aging differentially affects the loss of neuronal dendritic spine, neuroinflammation and memory impairment at rats after surgery. PLoS One 2014;9:e106837.
- Mahajan SD, Aalinkeel R, Reynolds JL, et al. Suppression of MMP-9 expression in brain microvascular endothelial cells (BMVEC) using a gold nanorod (GNR)-siRNA nanoplex. Immunol Invest 2012;41:337–55.
- Svedin P, Hagberg H, Sävman K, et al. Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. J Neurosci 2007;27:1511–8.
- Hu N, Guo D, Wang H, et al. Involvement of the blood–brain barrier opening in cognitive decline in aged rats following orthopedic surgery and high concentration of sevoflurane inhalation. Brain Res 2014;1551:13–24.
- Reijerkerk A, Kooij G, van der Pol SM, et al. Tissue-type plasminogen activator is a regulator of monocyte diapedesis through the brain endothelial barrier. J Immunol 2008;181:3567–74.
- Xu B, Li KP, Shen F, et al. Ulinastatin reduces cancer recurrence after resection of hepatic metastases from colon cancer by inhibiting MMP-9 activation via the antifibrinolytic pathway. Biomed Res Int 2013;2013:437950.
- Thal SC, Luh C, Schaible EV, et al. Volatile anesthetics influence blood–brain barrier integrity by modulation of tight junction protein expression in traumatic brain injury. PLoS One 2012;7:e50752.